Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 12/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1880629 | 0.88 | PIK3CD (0.54) | PIK3CDPIK3CGADORA2AADORA1PDE10A | |
| SCHEMBL1880927 | 0.80 | PIK3CD (0.41) | PIK3CD | |
| SCHEMBL1879180 | 0.77 | PIK3CD (0.57) | PIK3CDPIK3CGADORA2APDE10A | |
| SCHEMBL1888178 | 0.76 | PIK3CD (0.45) | PIK3CD | |
| SCHEMBL788288 | 0.74 | PIK3CD (1.00) | PIK3CD | |
| SCHEMBL716728 | 0.73 | PIK3CD (0.57) | PIK3CD | |
| SCHEMBL1877699 | 0.72 | PIK3CD (0.45) | PIK3CDADORA2AADORA1 | |
| SCHEMBL714331 | 0.71 | PIK3CD (0.59) | PIK3CDPIK3CG | |
| SCHEMBL1884628 | 0.71 | PIK3CD (0.40) | PIK3CDADORA2AADORA1 | |
| SCHEMBL859812 | 0.70 | PIK3CD (0.46) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | PIK3CD 8/4885PIK3CG 9/4885ADORA2A 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.